Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
November 22nd, 2009
Podcast 66: Niacin versus ezetimibe in the face of high cardiovascular risk — a conversation with the ARBITER 6-HALTS trialist Allen Taylor
One of the more intriguing pieces of research presented at the American Heart Association this week (and simultaneously released online in the New England Journal of Medicine) shows that extended-release niacin outperforms ezetimibe in high-risk patients. We talk with Dr. Allen J. Taylor, the study’s first author. Contact us at 1-617-440-4374 or write firstname.lastname@example.org. This [...]
May 23rd, 2009
This week we talk with Harlan Krumholz about his paper in BMJ. His team finds that the door-to-balloon-time recommendation of 90 minutes is too long and that many more lives could be saved by shortening that time. Listen to his thoughts on this. And I’d like to listen to your thoughts, which you may send [...]
May 17th, 2009
Podcast 43: An interview with Martha Gulati on her research into the cardiovascular risks faced by symptomatic women who have normal angiograms.
Northwestern’s Martha Gulati has just published a paper in Archives of Internal Medicine about the hazards of treating symptomatic women with normal angiograms as if they had a benign prognosis. We’ll talk with her after a look at the news, and a reminder that you can really help Clinical Conversations with your feedback. The place [...]
April 20th, 2009
Podcast 39: A conversation with Kimford Meador about a new paper assessing the later cognitive effects of fetal exposure to antiepileptic drugs.
Neurologists have talked about these effects for a while, but now they’ve got evidence showing that valproate lowers IQ at age 3 by almost 10 points. Since only half the antiepileptics are used in epilepsy, the results will affect everyone caring for women of reproductive age. Kimford Meador of Emory University is here to talk [...]
February 20th, 2009
Podcast 31: Making your clinical life easier — with genetics. Dr. Julie Johnson talks about using a patient’s genetic profile to help set their initial warfarin dose more accurately. You got a problem with that?
Starting a patient on warfarin is nobody’s idea of a good time, but pharmacogenetic research can help. A study in this week’s NEJM shows the advantage of using genetic information (plus some clinical data) over the old “start at 5 mg a day and pray for success” approach. We talk with Julie Johnson of the [...]
October 6th, 2008
Podcast 14: News roundup and interview with Dr. Michael Hochman about his JAMA paper on how the news media cover drug research.
The week ending Oct. 3, 2008, was relatively slow for medical news, but crammed with news of every other sort. This week’s interview features Michael Hochman, a third-year resident in internal medicine who has just published a paper on how the media cover research on new drugs. It seems they don’t make a habit of [...]